The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
During the 18th International Workshop on Non-Hogkin Lymphoma (iwNHL), the Chair of the Lymphoma Hub, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, spoke about the use of tafasitamab in patients with diffuse large B cell lymphoma (DLBCL).
Tafasitamab in DLBCL
Tafasitamab is a CD19-directed monoclonal antibody approved by the FDA in July 2020 for use in combination with lenalidomide as a second-line treatment for patients with relapsed or refractory (R/R) DLBCL. Approval was based on results from the phase II L-MIND study. In this interview, Gilles Salles discusses these results and questions how we might sequence the L-MIND regimen compared to chimeric antigen receptor (CAR) T cell therapy given that the epitope recognised by tafasitamab overlaps with the epitope targeted by CD19-directed CAR T cells.